DT-061 is a selective small molecule activator of the BCL-2 family protein BCL-XL. It is primarily used in research settings to study apoptosis regulation, particularly in cancer biology. By stabilizing BCL-XL and enhancing its anti-apoptotic activity, DT-061 helps investigate mechanisms of cell survival and resistance to cell death. It has been employed in studies involving hematologic malignancies and solid tumors to understand how modulation of BCL-XL affects chemoresistance and tumor progression. Additionally, DT-061 serves as a tool compound to validate BCL-XL as a therapeutic target and to explore combination therapies with other pro-apoptotic agents. Its use is confined to preclinical research due to its experimental nature.